Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q2 FY20 results · Jul–Sep 2019

Dr. Reddy's Laboratories reported revenue from operations of ₹4,812.80 crore (up 26.1% from Q2 FY19) and net profit of ₹1,106.80 crore (up 113.5% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	4,812.80	3,817.50	+26.1%	3,858.20	+24.7%
Other income	54.00	128.20	−57.9%	430.10	−87.4%
Total income	4,866.80	3,945.70	+23.3%	4,288.30	+13.5%
Profit before share of associates & JVs and tax	774.40	588.10	+31.7%	853.00	−9.2%
Share of profit/(loss) of associates & JVs	11.70	10.90		16.30
Net profit for the period	1,106.80	518.30	+113.5%	676.50	+63.6%
Attributable to shareholders of the company	1,095.10	518.30	+111.3%	—	—
EPS, basic (₹)	66.78	31.22	+113.9%	40.81	+63.6%
Net margin (%)	23.0	13.6		17.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY20	Q2 FY19	YoY	Q1 FY20	QoQ
Revenue from operations	3,446.00	2,631.00	+31.0%	2,508.70	+37.4%
Other income	76.70	74.80	+2.5%	471.40	−83.7%
Total income	3,522.70	2,705.80	+30.2%	2,980.10	+18.2%
Profit before tax	1,021.20	432.80	+136.0%	693.00	+47.4%
Net profit for the period	1,365.10	346.20	+294.3%	548.10	+149.1%
EPS, basic (₹)	82.36	20.86	+294.8%	33.06	+149.1%
Net margin (%)	39.6	13.2		21.8

Consolidated

Filed with BSE: 01 Nov 2019, 13:42 IST
Board meeting: 01 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 01 Nov 2019, 13:42 IST
Board meeting: 01 Nov 2019
Period: 01 Jul 2019 to 30 Sep 2019
Review status: Unaudited
Source: XBRL filing on BSE